214 related articles for article (PubMed ID: 22555080)
1. Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor.
James C; Preininger L; Sweet M
Am J Health Syst Pharm; 2012 May; 69(10):857-61. PubMed ID: 22555080
[TBL] [Abstract][Full Text] [Related]
2. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
Domingo P; Ribera E
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
[TBL] [Abstract][Full Text] [Related]
3. Rilpivirine. First-line treatment of HIV infection: efavirenz is better documented.
Prescrire Int; 2012 Nov; 21(132):262-5. PubMed ID: 23210255
[TBL] [Abstract][Full Text] [Related]
4. [Mechanism of action and pharmacokinetics of rilpivirine].
Portilla J; Estrada V
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():2-5. PubMed ID: 24252527
[TBL] [Abstract][Full Text] [Related]
5. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
[TBL] [Abstract][Full Text] [Related]
6. Rilpivirine, a novel non-nucleoside reverse transcriptase inhibitor for the management of HIV-1 infection: a systematic review.
Schafer JJ; Short WR
Antivir Ther; 2012; 17(8):1495-502. PubMed ID: 22878339
[TBL] [Abstract][Full Text] [Related]
7. Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor.
Sharma M; Saravolatz LD
J Antimicrob Chemother; 2013 Feb; 68(2):250-6. PubMed ID: 23099850
[TBL] [Abstract][Full Text] [Related]
8. Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials.
Molina JM; Clumeck N; Orkin C; Rimsky LT; Vanveggel S; Stevens M;
HIV Med; 2014 Jan; 15(1):57-62. PubMed ID: 23980523
[TBL] [Abstract][Full Text] [Related]
9. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
[TBL] [Abstract][Full Text] [Related]
10. The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy.
Imaz A; Podzamczer D
AIDS Rev; 2012; 14(4):268-78. PubMed ID: 23258301
[TBL] [Abstract][Full Text] [Related]
11. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine.
Crauwels H; van Heeswijk RP; Stevens M; Buelens A; Vanveggel S; Boven K; Hoetelmans R
AIDS Rev; 2013; 15(2):87-101. PubMed ID: 23681436
[TBL] [Abstract][Full Text] [Related]
12. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
Fulco PP; McNicholl IR
Pharmacotherapy; 2009 Mar; 29(3):281-94. PubMed ID: 19249947
[TBL] [Abstract][Full Text] [Related]
13. Rilpivirine: a new addition to the anti-HIV-1 armamentarium.
Miller CD; Crain J; Tran B; Patel N
Drugs Today (Barc); 2011 Jan; 47(1):5-15. PubMed ID: 21373646
[TBL] [Abstract][Full Text] [Related]
14. Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor.
Garvey L; Winston A
Expert Opin Investig Drugs; 2009 Jul; 18(7):1035-41. PubMed ID: 19548857
[TBL] [Abstract][Full Text] [Related]
15. [Resistance profile of rilpivirine].
Imaz A; García F; di Yacovo S; Llibre JM
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological properties of rilpivirine (Edurant Tablet), a new drug for the treatment of HIV, and results of its clinical studies].
Iwata M; Shikinami K; Nagino K; Harada Y
Nihon Yakurigaku Zasshi; 2013 Apr; 141(4):205-11. PubMed ID: 23575426
[No Abstract] [Full Text] [Related]
17. Rilpivirine vs. efavirenz in HIV-1 patients with baseline viral load 100,000 copies/ml or less: week 48 phase III analysis.
Molina JM; Clumeck N; Redant K; Rimsky L; Vanveggel S; Stevens M;
AIDS; 2013 Mar; 27(6):889-897. PubMed ID: 23276806
[TBL] [Abstract][Full Text] [Related]
18. Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.
Rokx C; Verbon A; Rijnders BJ
HIV Med; 2014 Nov; 15(10):611-4. PubMed ID: 24738660
[TBL] [Abstract][Full Text] [Related]
19. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
Gallien S; Charreau I; Nere ML; Mahjoub N; Simon F; de Castro N; Aboulker JP; Molina JM; Delaugerre C
J Antimicrob Chemother; 2015 Feb; 70(2):562-5. PubMed ID: 25344807
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of rilpivirine, a non-nucleoside reverse transcriptase inhibitor, in treatment-naive adults infected with HIV-1: a meta-analysis.
Li SL; Xu P; Zhang L; Sun GX; Lu ZJ
HIV Clin Trials; 2014; 15(6):261-8. PubMed ID: 25433665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
